RBM5 and breast carcinoma: Our present work provides new evidence that RBM5-AS1 maybe used as novel biomarker for breast cancer diagnosis and blocking the RBM5-AS1/Wnt/β-catenin axis can serve as a potential therapeutic target for breast cancer therapy.